Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment.
10.1097/CM9.0000000000002758
- Author:
Jingcheng ZHANG
1
;
Yutong WANG
2
;
Lejunzi WANG
3
;
Lei YOU
1
;
Taiping ZHANG
1
Author Information
1. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
3. Department of Anaesthesia, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Gemcitabine;
Deoxycytidine/therapeutic use*;
Drug Resistance, Neoplasm;
Metabolic Reprogramming;
Carcinoma, Pancreatic Ductal/drug therapy*;
Pancreatic Neoplasms/pathology*;
Cell Line, Tumor
- From:
Chinese Medical Journal
2024;137(4):408-420
- CountryChina
- Language:English
-
Abstract:
As pancreatic cancer (PC) is highly malignant, its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies. First-line chemotherapies for PC, according to current guidelines, include fluoropyrimidine- and gemcitabine-based regimens. Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC, especially those involving glycolysis and glutamine metabolism, are highly associated with chemoresistance. Additionally, lipid metabolism is a major factor in chemoresistance. However, emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance. This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.
